Glenmark Pharma FY27 guidance: ₹17,000-18,000 cr

What the company guided for

Glenmark Pharmaceuticals has reiterated confidence in achieving FY27 revenue of ₹17,000 crore to ₹18,000 crore, along with EBITDA margins of 21% to 22%. The management commentary also indicated that the India business is expected to continue growing at around 15%, described as mid-teens growth. The guidance places a clear marker for investors tracking the company’s operational reset and margin trajectory.

The same discussion also pointed to a longer-term change in sales mix, with the company targeting 70% of sales from branded products by 2030. Management said the branded contribution is around 60% currently, indicating an intended shift in portfolio and channel mix over the next few years.

Revenue and margin targets for FY27

In the management interaction, the revenue range was restated more than once as ₹17,000 crore to ₹18,000 crore for FY27. EBITDA margin expectations were specified as 21% to 22%. These are among the clearest numerical guideposts in the update.

A brokerage note in the provided material also referenced FY27 revenue guidance of ₹17,000 crore to ₹18,000 crore, and compared it with ₹13,300 crore cited as FY26 revenue. That implies a materially higher revenue base by FY27 versus FY26 in that model context, although the company’s own commentary in the excerpt focuses on confidence rather than detailing a bridge.

India business: mid-teens growth narrative

Management said the India business is continuing to grow at around close to 15%, and added that India should continue to deliver double-digit growth with the company aiming to outperform the market. While no base numbers for India were provided in the excerpt, the growth rate itself is an important input for forecasts because domestic formulations are often a stabilising segment for Indian pharma companies.

The mid-teens expectation also sits alongside brokerage projections that highlight domestic formulations as a key driver. One Motilal Oswal view in the text expects domestic formulations sales to compound at 25% over FY26 to FY28 and reach ₹5,770 crore (₹57.7 billion) by the end of that period.

Branded mix target: 70% by 2030

Management indicated the company is currently at 60% branded sales and is confident of reaching 70% by 2030. The excerpt does not specify the exact levers for this shift, but the target implies a greater push toward branded portfolios over time.

For investors, branded mix guidance is typically tracked because it can influence pricing power, product positioning, and margin profile. However, based on the provided text, the only confirmed points are the current level (60%) and the target (70% by 2030).

Motilal Oswal turns bullish: target ₹2,610

Motilal Oswal reiterated a BUY call on Glenmark Pharma with a target price of ₹2,610. The note cited a current market price (CMP) of ₹2,201 and an implied upside of 19% from that level. It also said it values the company at 25 times 12-month forward earnings to arrive at the target price.

In terms of operational assumptions, the same note expects US sales to grow at a 9% CAGR to ₹4,130 crore (₹41.3 billion). It expects Europe sales to grow at a 17% CAGR to ₹4,240 crore (₹42.4 billion), and emerging markets (EM) sales to rise at a 10% CAGR to ₹3,570 crore (₹35.7 billion) over FY26 to FY28.

Other brokerage targets and valuation inputs

The material also references multiple other price targets and model assumptions from analysts and research notes. One update mentioned analysts maintaining a fair value estimate of ₹2,735.00, and updating assumptions to reflect expectations of 10.47% revenue growth, a 14.62% profit margin, and a higher future P/E of 32.71x.

Another narrative update kept the analyst price target at ₹2,735, citing inputs such as 7.13% revenue growth, a 19.60% profit margin, and a future P/E of 27.61. Separately, another line in the text mentions an updated price target set around ₹1,532, reflecting adjustments to assumptions on revenue growth, profit margins, and forward P/E.

The excerpt also notes a modest upward revision in consensus price target to ₹2,246, attributed mainly to a slightly higher future P/E multiple, with revenue growth forecasts largely unchanged.

A snapshot of key numbers

Price targets and market reference points in the excerpt

Market impact: what investors are likely tracking

The most direct market framing in the excerpt comes from brokerage reports that pair a target price with the prevailing market price. For example, Motilal Oswal’s ₹2,610 target is benchmarked against a CMP of ₹2,201, while another note frames a ₹2,430 target against a price near ₹1,904, along with technical reference points such as support at ₹1,850 and resistance levels at ₹2,000 and ₹2,200.

On fundamentals, the focal points are the company’s ability to deliver the FY27 revenue and margin band, and whether segment momentum materialises as projected in the brokerage assumptions for the US, Europe, and other markets. The excerpt also flags R&D spend as an item that some analysts have factored into their earnings estimates.

Why the guidance matters

A stated FY27 revenue band of ₹17,000-18,000 crore with 21-22% EBITDA margin is a concrete benchmark that can influence how investors assess near-term execution. It also provides a basis for comparing differing valuation views, particularly when analysts use different margin assumptions, profit margin inputs, and future P/E multiples.

The longer-term branded mix ambition, moving from 60% to 70% by 2030, adds another layer for investors evaluating business quality and portfolio strategy. But based on the provided material, the only confirmed data points are the current mix and the 2030 target.

Conclusion

Glenmark Pharmaceuticals has reiterated FY27 guidance of ₹17,000-18,000 crore revenue and 21-22% EBITDA margin, while maintaining that the India business is growing at about 15% and aiming for a 70% branded sales mix by 2030 from 60% currently. Brokerages cited in the text show a wide spread of price targets and valuation inputs, with Motilal Oswal’s latest BUY view pointing to a ₹2,610 target against a ₹2,201 reference price. The next set of updates investors will watch are progress against the FY27 revenue and margin band and how key geographies track versus the growth assumptions outlined in brokerage models.